New obesity management medications, such as glucagon-like peptide-1 receptor agonists, have demonstrated promising results for weight reduction; however, sustainable long-term weight loss, especially after cessation of the drugs, has yet to be confirmed.9,10 Additionally, challenges persist with medication adherence and availability.11 Until further research provides more definitive long-term outcomes, metabolic bariatric surgery (MBS) remains the most effective and sustainable treatment for severe obesity.12,13. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.